Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

COVID-19 Vaccines: A Comprehensive Review of Development, Action Mechanisms, and Global Implications

Author(s): Sandhya Rajbahadur Yadav* and Pushpalata Chougule

Volume 5, Issue 4, 2024

Published on: 26 January, 2024

Article ID: e260124226331 Pages: 13

DOI: 10.2174/0126667975268518240111113733

Price: $65

conference banner
Abstract

The fast spread of SARS-CoV-2, the coronavirus pandemic virus, across the world presents a significant population health dilemma. Various protective measures were adopted to address this worldwide health crisis, and among those, the production of vaccines is of paramount importance. This review focuses on the prominent vaccines developed against the pandemic virus during the ongoing worldwide outbreak. The mechanisms of action for each vaccine resemble that of Pfizer's comirnaty in the United States of America, Moderna vaccine in the United States of America, and AstraZeneca's adenovirus-based vaccine developed by the UK's Oxford-based university. The demand for vaccines to counter pandemic corona virus, the pathogen behind COVID-19, is imperative. These vaccines, including those from Pfizer-BioNTech, Moderna, and AstraZeneca, are poised to play a pivotal role in addressing the urgent global need. This review seeks to offer an allencompassing perspective of the COVID-19 pandemic, including its epidemiology, transmission, advancements in treatment, vaccines, as well as the genetic variability and life cycle of the pandemic coronavirus, relying on the latest research in conjunction with available data.

Keywords: Pandemic COVID-19 vaccines, pandemic coronavirus, phases, DNA genomes, spike, SARS-CoV-2.

Graphical Abstract

[1]
Nile SH, Nile A, Jalde S, Kai G. Recent advances in potential drug therapies combating COVID-19 and related coronaviruses-A perspective. Food Chem Toxicol 2021; 154: 112333.
[http://dx.doi.org/10.1016/j.fct.2021.112333] [PMID: 34118347]
[2]
Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol 2021; 892: 173751.
[http://dx.doi.org/10.1016/j.ejphar.2020.173751] [PMID: 33245898]
[3]
Speiser DE, Bachmann MF. COVID-19: Mechanisms of vaccination and immunity. Vaccines 2020; 8(3): 404.
[http://dx.doi.org/10.3390/vaccines8030404] [PMID: 32707833]
[4]
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-8.
[http://dx.doi.org/10.1016/j.jare.2020.03.005] [PMID: 32257431]
[5]
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020; 26(4): 450-2.
[http://dx.doi.org/10.1038/s41591-020-0820-9] [PMID: 32284615]
[6]
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3): 181-92.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[7]
Xiong X, Qu K, Ciazynska KA, et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat Struct Mol Biol 2020; 27(10): 934-41.
[http://dx.doi.org/10.1038/s41594-020-0478-5] [PMID: 32737467]
[8]
Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res 2017; 137: 82-92.
[http://dx.doi.org/10.1016/j.antiviral.2016.11.006] [PMID: 27840203]
[9]
Sofi MS, Hamid A, Bhat SU. Coronavirus COVID-19: A critical review of its history, pathogenesis, transmission, diagnosis and treatment. Biosaf Health 2020.
[10]
Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infect Genet Evol 2020; 83: 104327.
[http://dx.doi.org/10.1016/j.meegid.2020.104327] [PMID: 32320825]
[11]
Tsai SC, Lu CC, Bau DT, et al. Approaches towards fighting the COVID 19 pandemic (Review). Int J Mol Med 2020; 47(1): 3-22.
[http://dx.doi.org/10.3892/ijmm.2020.4794] [PMID: 33236131]
[12]
COVID-19, Biography. Available from: https://www.ghanaweb.com/person/COVID-19
[13]
Adedeji AO, Singh K, Kassim A, et al. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother 2014; 58(8): 4894-8.
[http://dx.doi.org/10.1128/AAC.02994-14] [PMID: 24841268]
[14]
Binnicker MJ. Emergence of a novel coronavirus disease (COVID-19) and the importance of diagnostic testing: Why partnership between clinical laboratories, public health agencies, and industry is essential to control the outbreak. Clin Chem 2020; 66(5): 664-6.
[http://dx.doi.org/10.1093/clinchem/hvaa071] [PMID: 32077933]
[15]
Technical guidance publications Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance-publications
[16]
Li T. Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: An operational recommendation of Peking Union Medical College Hospital (V2.0). Emerg Microbes Infect 2020; 9(1): 582-5.
[http://dx.doi.org/10.1080/22221751.2020.1735265] [PMID: 32172669]
[17]
Morawska L, Cao J. Airborne transmission of SARS-CoV-2: The world should face the reality. Environ Int 2020; 139: 105730.
[http://dx.doi.org/10.1016/j.envint.2020.105730] [PMID: 32294574]
[18]
Abduljalil JM, Abduljalil BM. Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. New Microbes New Infect 2020; 35: 100672.
[http://dx.doi.org/10.1016/j.nmni.2020.100672] [PMID: 32322400]
[19]
Zhang Q, Xiang R, Huo S, et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther 2021; 6(1): 233.
[http://dx.doi.org/10.1038/s41392-021-00653-w] [PMID: 34117216]
[20]
Esteban-Zubero E, Esteban-Zubero E. COVID-19 pandemic and medical resident education. Iberoam J Med 2021; 3(1): 1-2.
[http://dx.doi.org/10.53986/ibjm.2021.0001]
[21]
Anti-SARS-CoV-2 Rapid Test A rapid one-step antibody test FDA Emergency Use Authorization (EUA) Approved (IgM and IgG). Available from: https://www.fda.gov/media/137367/download
[22]
Carter LJ, Garner LV, Smoot JW, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci 2020; 6(5): 591-605.
[http://dx.doi.org/10.1021/acscentsci.0c00501] [PMID: 32382657]
[23]
Mahendiratta S, Batra G, Sarma P, et al. Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review. Life Sci 2020; 258: 118207.
[http://dx.doi.org/10.1016/j.lfs.2020.118207] [PMID: 32777301]
[24]
Tu YF, Chien CS, Yarmishyn AA, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci 2020; 21(7): 2657.
[http://dx.doi.org/10.3390/ijms21072657] [PMID: 32290293]
[25]
Sun J, He WT, Wang L, et al. COVID-19: Epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med 2020; 26(5): 483-95.
[http://dx.doi.org/10.1016/j.molmed.2020.02.008] [PMID: 32359479]
[26]
Majila K, Lal S, Ahmad MF. COVID-19 pandemic: An overview of its origin, current status, and ongoing clinical trials. Coronaviruses. Int J Antimicrob Agents 2020; 55(5): 105951.
[PMID: 32234466]
[27]
Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020; 5(5): 434-5.
[http://dx.doi.org/10.1016/S2468-1253(20)30083-2] [PMID: 32199469]
[28]
Zheng J. SARS-coV-2: An emerging coronavirus that causes a global threat. Int J Biol Sci 2020; 16(10): 1678-85.
[http://dx.doi.org/10.7150/ijbs.45053] [PMID: 32226285]
[29]
Rahman H. Transmission, prevention, and therapeutic strategies for COVID-19: updates and challenges. Coronaviruses 2021; 02
[30]
Ledford H. What the immune response to the coronavirus says about the prospects for a vaccine. Nature 2020; 585(7823): 20-1.
[http://dx.doi.org/10.1038/d41586-020-02400-7] [PMID: 32811981]
[31]
Coronavirus disease (COVID-19): Vaccines and vaccine safety Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(COVID-19)-vaccines?adgroupsurvey=adgroupsurvey
[32]
The different types of COVID-19 vaccines. Available from: https://www.who.int/news-room/feature-stories/detail/the-race-for-a-COVID-19-vaccine-explained
[33]
Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19(5): 305-6.
[http://dx.doi.org/10.1038/d41573-020-00073-5] [PMID: 32273591]
[34]
Bar-On YM, Flamholz A, Phillips R, Milo R. SARS-CoV-2 (COVID-19) by the numbers. eLife 2020; 9: e57309.
[http://dx.doi.org/10.7554/eLife.57309] [PMID: 32228860]
[35]
Fauci AS, Lane HC, Redfield RR. COVID-19 — navigating the uncharted. N Engl J Med 2020; 382(13): 1268-9.
[http://dx.doi.org/10.1056/NEJMe2002387] [PMID: 32109011]
[36]
Coronavirus: WHO backed China’s emergency use of experimental vaccines, health official says. Available from: https://www.scmp.com/news/china/society/article/3103121/coronavirus-who-backed-chinas-emergency-use-experimental
[37]
Russia Is Slow to Administer Virus Vaccine Despite Kremlin’s Approval - The New York Times Available from: https://www.nytimes.com/2020/09/19/world/europe/russia-coronavirus-vaccine.html
[38]
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization
[39]
Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA. Available from: https://time.com/5914139/pfizer-COVID-19-vaccine-fda-authorization/
[40]
Kim JM, Chung YS, Jo HJ, et al. Identification of coronavirus isolated from a patient in Korea with COVID-19. Osong Public Health Res Perspect 2020; 11(1): 3-7.
[http://dx.doi.org/10.24171/j.phrp.2020.11.1.02] [PMID: 32149036]
[41]
Information for Healthcare Professionals on COVID-19 Vaccine Pfizer/BioNTech Available from: https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-COVID-19/information-for-healthcare-professionals-on-pfizerbiontech-COVID-19-vaccine
[42]
Questions and Answers COVID-19 vaccination in the EU* Available from: https://ec.europa.eu/commission/presscorner/detail/en/qanda_20_2467
[43]
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384(5): 403-16.
[http://dx.doi.org/10.1056/NEJMoa2035389] [PMID: 33378609]
[44]
Spikevax and Moderna COVID-19 Vaccine. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-COVID-19/spikevax-and-moderna-COVID-19-vaccine
[45]
These are the different COVID-19 vaccines, how they work, and their side effects. Available from: https://www.iol.co.za/news/world/these-are-the-different-COVID-19-vaccines-how-they-work-and-their-side-effects-0c471c3e-b519-46c4-ba86-2668012bf32b
[46]
COVID-19 Vaccines Advice Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/COVID-19-vaccines/advice
[47]
Understanding Viral Vector COVID-19 Vaccines Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/viralvector.html
[48]
Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv Drug Deliv Rev 2021; 179: 114000.
[http://dx.doi.org/10.1016/j.addr.2021.114000] [PMID: 34637846]
[49]
Verbeke R, Lentacker I, De Smedt SC, Dewitte H. The dawn of mRNA vaccines: The COVID-19 case. J Control Release 2021; 333: 511-20.
[http://dx.doi.org/10.1016/j.jconrel.2021.03.043] [PMID: 33798667]
[50]
There are four types of COVID-19 vaccines: Here’s how they work Available from: https://www.gavi.org/vaccineswork/there-are-four-types-COVID-19-vaccines-heres-how-they-work
[51]
What different types of COVID-19 vaccine are there?. Available from: https://wellcome.org/news/what-different-types-COVID-19-vaccine-are-there
[52]
Minet kenya COVID-19 vaccination advisory. 2021. Available from: http://www.minet.com/wp-content/uploads/2021/03/Kenya-vaccine.pdf
[53]
COVID 19: Where are we now? What have we learned in the last 12 months? Available from: https://www.theaustraliatoday.com.au/COVID-19-where-we-are-now-what-we-havelearnt-in-the-last-12-months/
[54]
How COVID unlocked the power of RNA vaccines. Available from: https://www.nature.com/articles/d41586-021-00019
[55]
Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB. SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ Vaccines 2021; 6(1): 1-17.
[56]
Why do we develop lifelong immunity to some diseases but not others?. Available from: https://healthmatch.io/blog/why-do-we-develop-lifelong-immunity-to-some-diseases-but-not-others
[57]
Nooraei S, Bahrulolum H, Hoseini ZS, et al. Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology 2021; 19(1): 59.
[http://dx.doi.org/10.1186/s12951-021-00806-7] [PMID: 33632278]
[58]
The Sinopharm COVID-19 vaccine: What you need to know. Available from: https://www.who.int/news-room/feature-stories/detail/the-sinopharm-COVID-19-vaccine-what-you-need-to-know
[59]
Making Vaccines: How Are Vaccines Made? Available from: https://www.chop.edu/centers-programs/vaccine-education-center/making-vaccines/how-are-vaccines-made
[60]
Salvatori G, Luberto L, Maffei M, et al. SARS-CoV-2 spike protein: An optimal immunological target for vaccines. J Transl Med 2020; 18(1): 222.
[http://dx.doi.org/10.1186/s12967-020-02392-y] [PMID: 32493510]
[61]
Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front Immunol 2021; 12: 701501.
[http://dx.doi.org/10.3389/fimmu.2021.701501] [PMID: 34322129]
[62]
Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016; 3(1): 237-61.
[http://dx.doi.org/10.1146/annurev-virology-110615-042301] [PMID: 27578435]
[63]
COVID vaccination programme. Available from: www.easevidya.com
[64]
Advance Research Journal of Medical and Clinical Science Evaluation of the Moderna, Pfizer/Biotech, Astrazeneca/Oxford and Sputnik V Vaccines for COVID-19. Available from: https://www.academia.edu/45018650/
[65]
Xu AM, Li D, Ebinger JE, et al. Differences in SARS-CoV-2 vaccine response dynamics between class-I- and Class-II-specific t-cell receptors in inflammatory bowel disease. Front Immunol 2022; 13(April): 880190.
[http://dx.doi.org/10.3389/fimmu.2022.880190] [PMID: 35464463]
[66]
Evaluation of the moderna, pfizer/biotech, astrazeneca/oxford and sputnik V vaccines for COVID-19. Adv Res J Med Clin Sci 2021; 7(1)
[67]
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27(7): 1205-11.
[http://dx.doi.org/10.1038/s41591-021-01377-8] [PMID: 34002089]
[68]
Nguyen THO, Cohen CA, Rowntree LC, et al. T cells targeting SARS-CoV-2: By infection, vaccination, and against future variants. Front Med 2021; 8: 793102.
[http://dx.doi.org/10.3389/fmed.2021.793102] [PMID: 35004764]
[69]
Whitaker HJ, Tsang RSM, Byford R, et al. Pfizer-BioNTech and oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. J Infect 2022; 84(5): 675-83.
[http://dx.doi.org/10.1016/j.jinf.2021.12.044] [PMID: 34990709]
[70]
Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. BMJ 2021; 373(: n1088)
[http://dx.doi.org/10.1136/bmj.n1088] [PMID: 33985964]
[71]
Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe COVID-19 during predominant circulation of the delta variant in Italy: Retrospective cohort study. BMJ 2022; 376: e069052.
[http://dx.doi.org/10.1136/bmj-2021-069052] [PMID: 35144968]
[72]
del Cura-Bilbao A, López-Mendoza H, Chaure-Pardos A, Vergara-Ugarriza A, Guimbao-Bescós J. Effectiveness of 3 COVID-19 vaccines in preventing SARS-CoV-2 infections, January–May 2021, Aragon, Spain. Emerg Infect Dis 2022; 28(3): 591-8.
[http://dx.doi.org/10.3201/eid2803.212027] [PMID: 35195514]
[73]
Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn 2020; 39(9): 3409-18.
[http://dx.doi.org/10.1080/07391102.2020.1758788]
[74]
Yahya MQ, Hamed ZS, Kasim SM. Review research a comprehensive review of a race of vaccination against COVID-19 virus : The recent vaccines GJPHM 3(2): 447-56.
[75]
Pulendran B, S Arunachalam P, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov 2021; 20(6): 454-75.
[http://dx.doi.org/10.1038/s41573-021-00163-y] [PMID: 33824489]
[76]
COVID-19 Viral Vector Vaccines Available from: https://www.idsociety.org/COVID-19-real-time-learning-network/vaccines/COVID-19-viral-vector-vaccines/
[77]
The Oxford/AstraZeneca Available from: https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-
[78]
Bhatnagar T, Chaudhuri S, Ponnaiah M, Yadav PD, Sabarinathan R, Sahay RR. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: A multi-centric hospital-based case-control study. Int J Infect Dis 2021; 122: 693-702.
[79]
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397(10269): 99-111.
[http://dx.doi.org/10.1016/S0140-6736(20)32661-1] [PMID: 33306989]
[80]
Mohandas S, Yadav PD, Shete-Aich A, et al. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. iScience 2021; 24(2): 102054.
[http://dx.doi.org/10.1016/j.isci.2021.102054] [PMID: 33521604]
[81]
Mohan A, Suri TM, Ghosh T, et al. Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients. Lung India 2022; 39(3): 305-6.
[http://dx.doi.org/10.4103/lungindia.lungindia_141_22] [PMID: 35488692]
[82]
Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: A comparative review. Immunol Res 2022; 70(3): 289-315.
[http://dx.doi.org/10.1007/s12026-022-09265-0] [PMID: 35192185]
[83]
Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect Dis 2021; 21(7): 939-49.
[http://dx.doi.org/10.1016/S1473-3099(21)00224-3] [PMID: 33930320]
[84]
Ganesan S, Al Ketbi LMB, Al Kaabi N, et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE—An observational study. Front Public Health 2022; 10: 876336.
[http://dx.doi.org/10.3389/fpubh.2022.876336] [PMID: 35602146]
[85]
Omeish H, Najadat A, Al-Azzam S, et al. Reported COVID-19 vaccines side effects among Jordanian population: A cross sectional study. Hum Vaccin Immunother 2022; 18(1): 1981086.
[http://dx.doi.org/10.1080/21645515.2021.1981086] [PMID: 34614383]
[86]
Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol 2015; 13: 123-9.
[http://dx.doi.org/10.1016/j.coviro.2015.06.009] [PMID: 26184451]
[87]
Rockx B, Kuiken T, Herfst S, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 2020; 368(6494): 1012-5.
[http://dx.doi.org/10.1126/science.abb7314] [PMID: 32303590]
[88]
Bao L, Deng W, Huang B, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020; 583(7818): 830-3.
[http://dx.doi.org/10.1038/s41586-020-2312-y] [PMID: 32380511]
[89]
R&D Blueprint and COVID-19 Available from: https://www.who.int/teams/blueprint/COVID-19
[90]
Damodharan K, Arumugam GS, Ganesan S, Doble M, Thennarasu S. A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2. RSC Advances 2021; 11(33): 20006-35.
[http://dx.doi.org/10.1039/D0RA09668G] [PMID: 35479882]
[91]
Bahouq H, Bahouq M, Soulaymani A, Soulaymani-Bencheikh R. Pharmacovigilance in COVID-19 vaccines. E3S Web of Conferences. 319: 01012.
[92]
COVID-19 vaccination in India. Available from: https://en.wikipedia.org/wiki/COVID-19_vaccination_in_India
[93]
OpenWHO Knowledge for Health Available from: https://play.google.com/store/apps/details?id=de.xikolo.openwho&hl=en_IN&gl=US

Rights & Permissions Print Cite
Article Metrics
9
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy